New form of existing wake-promoting drug approved

Article

The FDA has given the go-ahead to Cephalon Inc. to market armodafinil (Nuvigil) for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift-work sleep disorder.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Image Credit: jokekung - stock.adobe.com
Image Credit: gamelover - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.